Biosergen AB (BIOSGN.ST)
SEK 0.51
(-5.9%)
SEK 0.51
(-5.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.08 Million SEK | -53.76% |
| 2022 | 10.99 Million SEK | 18.84% |
| 2021 | 9.25 Million SEK | -41.14% |
| 2020 | 15.72 Million SEK | 38.26% |
| 2019 | 11.37 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.72 Million SEK | -8.85% |
| 2024 Q1 | 4.08 Million SEK | -19.74% |
| 2023 Q4 | 5.08 Million SEK | 27.19% |
| 2023 FY | 5.08 Million SEK | -53.76% |
| 2023 Q3 | 3.99 Million SEK | -51.41% |
| 2023 Q2 | 8.22 Million SEK | 6.73% |
| 2023 Q1 | 7.7 Million SEK | -29.89% |
| 2022 Q2 | 7.05 Million SEK | 98.29% |
| 2022 Q1 | 3.56 Million SEK | -61.53% |
| 2022 FY | 10.99 Million SEK | 18.84% |
| 2022 Q4 | 10.99 Million SEK | -46.89% |
| 2022 Q3 | 20.7 Million SEK | 193.29% |
| 2021 Q2 | 6.93 Million SEK | 2672.4% |
| 2021 Q4 | 9.25 Million SEK | -10.42% |
| 2021 Q3 | 10.32 Million SEK | 49.03% |
| 2021 FY | 9.25 Million SEK | -41.14% |
| 2021 Q1 | 250 Thousand SEK | 0.0% |
| 2020 FY | 15.72 Million SEK | 38.26% |
| 2019 FY | 11.37 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 95.23% |
| Ziccum AB (publ) | 6.38 Million SEK | 20.398% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -115.557% |
| BioArctic AB (publ) | 139.5 Million SEK | 96.355% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 85.305% |
| Mendus AB (publ) | 51.22 Million SEK | 90.073% |
| Genovis AB (publ.) | 98.04 Million SEK | 94.814% |
| Intervacc AB (publ) | 21.68 Million SEK | 76.545% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 80.961% |
| Active Biotech AB (publ) | 13.4 Million SEK | 62.052% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 95.898% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 68.449% |
| Aptahem AB (publ) | 8.99 Million SEK | 43.486% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 87.555% |
| Kancera AB (publ) | 17.97 Million SEK | 71.715% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 88.989% |
| Fluicell AB (publ) | 8.91 Million SEK | 42.961% |
| Saniona AB (publ) | 86.08 Million SEK | 94.093% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 1.415% |
| Biovica International AB (publ) | 34.76 Million SEK | 85.374% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 56.419% |
| AcouSort AB (publ) | 10.37 Million SEK | 51.002% |
| Xintela AB (publ) | 14.01 Million SEK | 63.717% |
| Abliva AB (publ) | 16.78 Million SEK | 69.698% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.63% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 56.046% |
| OncoZenge AB (publ) | 1.69 Million SEK | -199.294% |
| Amniotics AB (publ) | 10.54 Million SEK | 51.787% |
| 2cureX AB (publ) | 2.93 Million SEK | -73.254% |
| CombiGene AB (publ) | 4.15 Million SEK | -22.353% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -14.889% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.675% |
| Camurus AB (publ) | 414.81 Million SEK | 98.774% |
| Corline Biomedical AB | 6.78 Million SEK | 25.099% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 91.712% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 73.466% |
| I-Tech AB | 16.2 Million SEK | 68.621% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.571% |
| Cyxone AB (publ) | 4.69 Million SEK | -8.33% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 61.847% |
| Cantargia AB (publ) | 54.97 Million SEK | 90.749% |
| NextCell Pharma AB | 13.68 Million SEK | 62.854% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 92.923% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 63.076% |
| Nanologica AB (publ) | 79.32 Million SEK | 93.59% |
| SynAct Pharma AB | 51.83 Million SEK | 90.19% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 36.03% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 2.116% |
| LIDDS AB (publ) | 3.75 Million SEK | -35.383% |
| Lipum AB (publ) | 7.53 Million SEK | 32.542% |
| BioInvent International AB (publ) | 90.45 Million SEK | 94.378% |
| Alzinova AB (publ) | 9.33 Million SEK | 45.504% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.2% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -183.445% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 72.505% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -32.491% |
| Simris Alg AB (publ) | 148.93 Million SEK | 96.586% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 92.85% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.945% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 60.099% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 29.959% |